# Regeneron Pharmaceuticals, Inc. (REGN) — Q2-2024 Earnings Results

**Report date:** 2024-08-01 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q2-2024

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 1.29%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $11.56 | N/A | +29.47% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. However, they did not provide specific revenue figures or future guidance.

**Key quotes:**

> We are pleased with our EPS performance this quarter.

> Our focus remains on innovation and delivering value to patients.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Regeneron's strong EPS performance, exceeding expectations by nearly 30%, led to a positive stock reaction, with shares rising 1.29%. The lack of revenue data and guidance leaves some uncertainty, but the management's optimistic tone suggests confidence in future performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q2-2024_